Genmab — November 2018

Bulder

The excitement in the conclusion is modest: Dara-CyBorD was active and well tolerated

Bulder

I'll ask Winkel if the results are worth a large phase 3 study.

E_L

yes, true, i was more thinking compared to the studies we already now, the Polux/ Alcyone/Maia etc, sry

E_L

But would be a good question...

E_L

it may have a different toxicity profile and therefore still be good for some patients even if the results would be a bit disapointing?

E_L

the more options the better i guess…

Bulder

I see. No doubt that Griffin pts are better than Maia pts. But equal to Cass pts.

Bulder

I remember Michael E O'Dwyer in a video saying that DRd or DRVd suffers from a considerable financial toxicity. The Irish can't afford it.

Solsen

In 2023 R goes off patent...

Bulder

Regarding Maia and Griffin. In Griffin we had 100% vgpr or better. I don't think we'll se that in Maia. But hopefully 100% PR or better.

E_L

it looks like Cyclophosphamide is a lot cheaper? Not sure if the dosing is 100% correct, but differnce looks large
http://ascopubs.org/doi/pdfdirect/10.1200/EDBK_200867

gentogen

Det lille CybordD har fulgt patienterne længere (post asct): "Responses deepened post ASCT with 100% achieving ≥ VGPR and 62% achieving ≥ CR. Based on EBMT criteria the CR/nCR rate post ASCT was 92%. Post ASCT PET-CT scans were consistent with complete metabolic response in all 13 patients". Ved ikke, jvad der ellers ses, men lyder vel OK.

Solsen

HR er tilsyneladende med seneste opdatering 0,43 i Alcyone - på ASCO stod der 0,5.

JørgenVarnæs

hold da op - det er da en udvikling, der er til at mærke. Så er det bare om at de andre fase 3 data kan udvikle sig på sammen måde/retning

Bulder

Og endnu mere bemærkelsesværdigt idet pfs for VMP er øget med 1 måned http://www.multiplemyelomahub.com/medical-information/ash-2017-phase-iii-alcyone-clinical-trial-daratumumab-plus-bortezomib-melphalan-and-prednisone-d-vmp-in-ndmm-patients-ineligible-for-transplant

Solsen

https://ash.confex.com/ash/2018/webprogram/start.html#srch=words|Adct 301|method|and|pge|1|byDayany|any|bySymposiumany|any|byAudienceany|any 5 orale præsentationer med ADCT 301 ! Mon ikke Genmab skulle have benyttet opt.in.

Solsen

Ja den ekstra måned er også interessant. Så det kan godt rykke lidt på tallene med tiden....

Bulder

Hvis Maia gør ligeså er vi nede i 0,4'erne til næste år.

peter12

Er det korrekt forstået at HR bliver forbedret fordi PFS for DVMP flader ud mens VMP ikke gør ? Det ser ud som om at VMP også flader ud nu

Bulder

Bluebird forsætter op. Gad vist om det er bb21217 eller LentiGlobin? https://seekingalpha.com/filing/4219307?app=1